These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22235415)

  • 1. Reduced content of α-synuclein in peripheral blood leukocytes of patients with LRRK2-associated Parkinson's disease.
    Pchelina SN; Emelyanov AK; Yakimovskii AF; Miller DW; Shabalina IG; Drozdova AS; Schwarzman AL
    Bull Exp Biol Med; 2011 Apr; 150(6):679-81. PubMed ID: 22235415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients.
    Tan YY; Wu L; Zhao ZB; Wang Y; Xiao Q; Liu J; Wang G; Ma JF; Chen SD
    Parkinsonism Relat Disord; 2014 Mar; 20(3):308-13. PubMed ID: 24398085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease.
    Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P
    Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388
    [No Abstract]   [Full Text] [Related]  

  • 5. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
    Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
    Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
    Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
    Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.
    Guerreiro PS; Huang Y; Gysbers A; Cheng D; Gai WP; Outeiro TF; Halliday GM
    J Mol Med (Berl); 2013 Apr; 91(4):513-22. PubMed ID: 23183827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
    Cookson MR
    Nat Rev Neurosci; 2010 Dec; 11(12):791-7. PubMed ID: 21088684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autosomal dominant Parkinson's disease and the route to new therapies.
    Morris HR
    Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of central and peripheral nervous system synuclein pathology in R1441G
    Vilas D; Gelpi E; Aldecoa I; Grau O; Rodriguez-Diehl R; Jaumà S; Martí MJ; Tolosa E
    J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):832-833. PubMed ID: 30054313
    [No Abstract]   [Full Text] [Related]  

  • 12. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
    Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
    Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants.
    Xiromerisiou G; Hadjigeorgiou GM; Gourbali V; Johnson J; Papakonstantinou I; Papadimitriou A; Singleton AB
    Eur J Neurol; 2007 Jan; 14(1):7-11. PubMed ID: 17222106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SNCA (A53T, A30P, E46K) and LRRK2 (G2019S) mutations are rare cause of Parkinson's disease in South Indian patients.
    Vishwanathan Padmaja M; Jayaraman M; Srinivasan AV; Srikumari Srisailapathy CR; Ramesh A
    Parkinsonism Relat Disord; 2012 Jul; 18(6):801-2. PubMed ID: 22436655
    [No Abstract]   [Full Text] [Related]  

  • 16. Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.
    Devine MJ; Lewis PA
    FEBS J; 2008 Dec; 275(23):5748-57. PubMed ID: 19021752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Αlpha-synuclein levels in blood plasma from LRRK2 mutation carriers.
    Gorostidi A; Bergareche A; Ruiz-Martínez J; Martí-Massó JF; Cruz M; Varghese S; Qureshi MM; Alzahmi F; Al-Hayani A; López de Munáin A; El-Agnaf OM
    PLoS One; 2012; 7(12):e52312. PubMed ID: 23300640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum.
    Westerlund M; Ran C; Borgkvist A; Sterky FH; Lindqvist E; Lundströmer K; Pernold K; Brené S; Kallunki P; Fisone G; Olson L; Galter D
    Mol Cell Neurosci; 2008 Dec; 39(4):586-91. PubMed ID: 18790059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.
    Gomez A; Ferrer I
    Acta Neuropathol; 2010 Aug; 120(2):155-67. PubMed ID: 20232069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.